MedTrace Logo

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

NCT06401707 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-07-08

No results posted yet for this study

Summary

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

Conditions

  • Heart Arrest
  • Seizures
  • Status Epilepticus

Interventions

DRUG

Perampanel

Perampanel is a non-competitive AMPA glutamate receptor antagonist.

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Edilberto Amorim, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2026-05-20
Completion
2026-10-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06401707 on ClinicalTrials.gov